As the global population ages the impact of neurodegenerative diseases like Alzheimer's disease and Parkinson's disease are significant forces in shaping human health and quality of life in the 21st century. Insights into understanding these diseases, and knowing how to treat them are major frontiers of scientific research. Neurodegenerative Diseases: Unifying Principles is the result of a conceptual revolution over the last decade in our understanding of neurodegenerative diseases as sharing unifying features. There is an increasing appreciation of the common biological and pathological features across seemingly varied neurodegenerative diseases that entail protein misfolding dysfunction and its consequences over time. Providing an overview of this conceptual change is the main theme for the book. Conventional approach emphasize the differences among neurodegenerative disorders, here Drs. Cummings and Pillai compile the increasingly compelling evidence that these disorders share many features and that insights in one may be rapidly translated into advances in another. The goal is to accelerate understanding by showing linkages among biological, pathological, can clinical aspects of this class of diseases. This collection of 19, inter-related chapters, articulates and broadens our view of the unifying features that initiate and drive disease progression across a variety of neurodegenerative diseases over time. This book will serve as an outstanding sourcebook of insights from experts that have played key roles in this story.

Growth in the incidence of dementia presents major challenges to global healthcare systems. As the burden of dementia in non-Western cultures grows, developing nations are expected to overtake developed nations in terms of dementia prevalence. Insights from developing nations and transcultural considerations are, nevertheless, neglected in the published literature. Dementia: A Global Approach fills this gap by integrating contemporary cross-cultural knowledge about dementia. Each section reviews the literature from the published, predominantly Western, perspective, contrasting it with empirical knowledge from non-Western cultures. Covering major clinical, epidemiological and scientific areas of interest, detailed consideration is also given to care-giving models across the world and management of patients who have migrated between regions. Enriched with personal insights from clinical experts across the globe, this is a key text for neurologists, geriatricians, psychiatrists, psychologists, epidemiologists and all those responsible for managing provisions of dementia services.

Published annually, volumes in this series provide readers with updates of clinical trial results, impacts of trials on guidelines and evidence-based practice, advances in trial methodologies, and the evolution of biomarkers in trials. The series focuses on trials in neurotherapeutics, including disease-modifying and symptomatic agents for neurological diseases, psychopharmacological management of neurologic and psychiatric illnesses, and non-drug treatments. Each paper is authored by a leader in the area of neurotherapeutics and clinical trials, and the series is guided by an editor-in-chief and editorial board with broad experience in drug development and neuropsychopharmacology. Progress in Neurotherapeutics and Neuropsychopharmacology is an essential update of trials in all aspects of the management of neurologic and neuropsychiatric disorders, and will be an invaluable resource for practising neurologists as well as clinical and translational neuroscientists.

Published annually, volumes in this series provide readers with updates of clinical trial results, impacts of trials on guidelines and evidence-based practice, advances in trial methodologies, and the evolution of biomarkers in trials. The series focuses on trials in neurotherapeutics, including disease-modifying and symptomatic agents for neurological diseases, psychopharmacological management of neurologic and psychiatric illnesses, and non-drug treatments. Each paper is authored by a leader in the area of neurotherapeutics and clinical trials, and the series is guided by an editor-in-chief and editorial board with broad experience in drug development and neuropsychopharmacology. Progress in Neurotherapeutics and Neuropsychopharmacology is an essential update of trials in all aspects of the management of neurologic and neuropsychiatric disorders, and will be an invaluable resource for practising neurologists as well as clinical and translational neuroscientists. This volume was first published in 2006.

Published annually, volumes in this series provide readers with updates of recent clinical trial results, impacts of trials on guidelines and evidence-based practice, advances in trial methodologies, and the evolution of biomarkers in trials. The series focuses on trials in neurotherapeutics, including disease-modifying and symptomatic agents for neurological diseases, psychopharmacological management of neurologic and psychiatric illnesses, and non-drug treatments. Each paper is authored by a leader in the area of neurotherapeutics and clinical trials, and the series is guided by an editor-in-chief and editorial board with broad experience in drug development and neuropsychopharmacology.
Progress in Neurotherapeutics and Neuropsychopharmacology" is an essential update of recent trials in all aspects of the management of neurologic and neuropsychiatric disorders, and will be an invaluable resource for practicing neurologists as well as clinical and translational neuroscientists.

Published annually, volumes in this series provide readers with updates of recent clinical trial results, impacts of trials on guidelines and evidence-based practice, advances in trial methodologies, and the evolution of biomarkers in trials. The series focuses on trials in neurotherapeutics, including disease-modifying and symptomatic agents for neurological diseases, psychopharmacological management of neurologic and psychiatric illnesses, and non-drug treatments. Each paper is authored by a leader in the area of neurotherapeutics and clinical trials, and the series is guided by an editor-in-chief and editorial board with broad experience in drug development and neuropsychopharmacology. Progress in Neurotherapeutics and Neuropsychopharmacology is an essential update of recent trials in all aspects of the management of neurologic and neuropsychiatric disorders, and will be an invaluable resource for practising neurologists as well as clinical and translational neuroscientists.

Published annually, volumes in this series provide readers with updates of recent clinical trial results, impacts of trials on guidelines and evidence-based practice, advances in trial methodologies, and the evolution of biomarkers in trials. The series focuses on trials in neurotherapeutics, including disease-modifying and symptomatic agents for neurological diseases, psychopharmacological management of neurologic and psychiatric illnesses, and non-drug treatments. Each paper is authored by a leader in the area of neurotherapeutics and clinical trials, and the series is guided by an editor-in-chief and editorial board with broad experience in drug development and neuropsychopharmacology. Progress in Neurotherapeutics and Neuropsychopharmacology is an essential update of recent trials in all aspects of the management of neurologic and neuropsychiatric disorders, and will be an invaluable resource for practising neurologists as well as clinical and translational neuroscientists. Also available electronically http: //www.journals.cambridge.org/jid_PNN.

For nearly 30 years, the Concise Guide to Neuropsychiatry and Behavioral Neurology has been an indispensable companion for clinicians caring for patients struggling with everything from delusions and hallucinations to aphasia and stroke. This third edition combines all of the scientific rigor of its predecessors with a renewed emphasis on kind, empathetic care. It has been updated to account for the development of new techniques in brain imaging; improvement in electrophysiological methods to better detect epilepsy and sleep disorders; and a growing list of blood and spinal fluid biomarkers that have revolutionized diagnostic capability. Readers will benefit from guidance on novel treatments and improved therapies for a range of disorders that includes * Memory disorders* Movement disorders* Brain tumors* Substance related disorders* HIV neurocognitive disorders A wealth of tables throughout the book will help busy clinicians quickly reference relevant information, regardless of the patient's presentation. And an extensive list of recommended readings opens the door to further study. As useful for trainees as it is for the experienced practitioner, the Concise Guide to Neuropsychiatry and Behavioral Neurology, Third Edition offers the latest science and expert guidance to both achieve accurate diagnosis and undertake effective management of patients with complex neuropsychiatric and neurobehavioral disorders.

Behavior and Mood Disorders in Focal Brain Lesions takes a unique approach to presenting the emotional and behavioral consequences of focal lesions affecting the brain to summarize the current state of research and provide a basis for improved patient care. This is the first clinical reference work to specifically address the relationship of focal brain dysfunction to behavioral and emotional disorders, providing the most comprehensive account available of these manifestations of brain lesions including stroke, trauma, epilepsy, multiple sclerosis, and even neurosurgery. A worldwide team of neuroscientists and clinicians examines the links between regional brain dysfunction and disorders of mood, thought and affect processing, and behavior. Chapters are devoted to methodological issues, lesions of specific sites, such as the frontal lobes, basal ganglia, and thalamus, and symptoms such as mood disorder, violent behavior, and anosognosia.

This is the long-awaited new edition of Jeffrey Cummings' classic work, Clinical Neuropsychiatry, originally published in 1985. That book represented an integration of behavioural neurology and biological psychiatry into a single volume devoted to explicating brain-behaviour relationships. It was clinically oriented and intended for practitioners caring for patients with neuropsychiatric disorders. The new title reflects the authors' effort to link the recent explosion of new information from neurochemistry, neuroanatomy, genetics, neuropharmacology, neuropathology, and neuroimaging to the clinical descriptions. Yet the clinical emphasis of its predecessor has been maintained. Each chapter has a consistent approach and the book as whole provides a practical, easy-to-use synthesis of clinical advice and basic science. The volume is enchanced by 4-colour images throughout. It is intended for students, residents, fellows, and practitioners of neurology, psychiatry, neuropsychology, and cognitive neuroscience. It will also be interest to individuals in neuroimaging.

Published annually, volumes in this series provide readers with updates of recent clinical trial results, impacts of trials on guidelines and evidence-based practice, advances in trial methodologies, and the evolution of biomarkers in trials. The series focuses on trials in neurotherapeutics, including disease-modifying and symptomatic agents for neurological diseases, psychopharmacological management of neurologic and psychiatric illnesses, and non-drug treatments. Each paper is authored by a leader in the area of neurotherapeutics and clinical trials, and the series is guided by an editor-in-chief and editorial board with broad experience in drug development and neuropsychopharmacology.
Progress in Neurotherapeutics and Neuropsychopharmacology" is an essential update of recent trials in all aspects of the management of neurologic and neuropsychiatric disorders, and will be an invaluable resource for practicing neurologists as well as clinical and translational neuroscientists.

Dementia with Lewy bodies (DLB) is among the most common causes of degenerative dementia. This book, which represents the first authoritative statement about DLB, includes review articles, case studies, and recent research findings from the leading researchers of DLB. The aims of this volume are to establish clinical diagnostic criteria and pathological protocols for DLB, and to explore evidence indicating that DLB patients may be responsive to symptomatic therapy. Covering the classification, cognitive manifestations, clinical diagnosis, epidemiology, genetics, neuropathology, neurochemistry, and treatment of DLB, this is a landmark publication in clinical neuroscience.